导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.08% | 3893/4773 |
| 近一周 | -2.38% | 2014/5462 |
| 近一月 | -1.72% | 1020/5421 |
| 近一季 | -2.20% | 1209/5209 |
| 近半年 | -7.45% | 3218/4920 |
| 近一年 | -17.10% | 3833/4366 |
| 近两年 | 25.74% | 2466/2954 |
| 近三年 | 24.23% | 1314/2253 |
| 成立以来 | -8.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.33% 4276/4961 |
-11.26% 4261/5312 |
- - |
- - |
| 2025 | 20.23% 2138/4813 |
15.96% 149/3635 |
1.37% 2364/4076 |
10.33% 3302/4524 |
-7.29% 3786/4813 |
| 2024 | 32.60% 84/3463 |
1.80% 853/2808 |
12.60% 20/3014 |
15.86% 1607/3129 |
-0.16% 1332/3463 |
| 2023 | -14.78% 1618/2656 |
-0.75% 1824/2280 |
-1.75% 524/2385 |
-6.62% 1488/2515 |
-6.42% 1767/2655 |
| 2022 | -7.61% 146/2207 |
-9.86% 359/1919 |
8.30% 374/2016 |
-15.45% 1294/2113 |
11.94% 134/2208 |
| 2021 | -18.99% 1172/1822 |
3.32% 186/1255 |
-2.42% 1205/1330 |
-13.89% 1360/1466 |
-6.69% 1544/1822 |
| 2020 | -7.16% 985/1250 |
-11.49% 840/1028 |
2.31% 975/1067 |
-6.38% 1120/1164 |
9.51% 637/1184 |
| 2019 | 12.77% 714/1092 |
8.79% 728/739 |
-0.63% 272/788 |
-3.25% 734/850 |
7.82% 393/918 |
| 2018 | - - |
- - |
-2.05% 62/631 |
4.89% 67/660 |
-8.21% 83/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方恒生国企ETF联接C VS. 长安沪深300非周期A(740101) |